Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Ono Pharmaceutical, Eurofarma, Dong-A - LARVOL DELTA

Pharmacokinetic variability and complex two-way interactions with cenobamate in patients with refractory epilepsy. (PubMed, Epilepsia) - "We demonstrate complex and unpredictable two-way interactions in polytherapy with CNB and pronounced pharmacokinetic variability among patients with refractory epilepsy, elucidating the usefulness of TDM."

Journal • PK/PD data • CNS Disorders • Epilepsy

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures (clinicaltrials.gov) - P3 | N=140 | Active, not recruiting | Sponsor: SK Life Science, Inc. | Trial completion date: Jul 2026 ➔ Nov 2026 | Trial primary completion date: May 2026 ➔ Nov 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy • Pediatrics

Pembrolizumab-induced Multifocal, Musicogenic, Autoimmune Epilepsy due to GAD65 Autoantibodies in a Patient Treated for Triple Negative Breast Cancer (AAN 2026) - "Design/ The patient was a 34-year-old, right-handed female with a past medical history of type 1 diabetes mellitus, hypogammaglobulinemia, systemic lupus erythematosus and triple-negative breast cancer due to the BRAC1 mutation who underwent a clinical trial with a neoadjuvant regimen of pembrolizumab plus carboplatin and docetaxel...She was maintained on intravenous immunoglobulin, hydroxychloroquine and mycophenolic acid for immunotherapy and clobazam, lamotrigine, levetiracetam, lorazepam and cenobamate for antiseizure medications. This case report describes a phenotypic evolution of GAD65 disease from adult-onset, type 1 diabetes mellitus to multifocal, musicogenic, drug-resistant autoimmune epilepsy after pembrolizumab use."

Clinical • IO biomarker • Breast Cancer • CNS Disorders • Diabetes • Epilepsy • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Oncology • Solid Tumor • Systemic Lupus Erythematosus • Triple Negative Breast Cancer • Type 1 Diabetes Mellitus

CENSUS: Cenobamate Efficacy in Individuals With Autoimmune Epilepsy (clinicaltrials.gov) - P=N/A | N=30 | Enrolling by invitation | Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

New trial • Real-world evidence • CNS Disorders • Epilepsy • Immunology

Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift? (PubMed, Neurol Ther) - "In this real-world study, early third-line CNB exhibits potentially favorable effectiveness compared with other commonly used third-line ASMs, and tolerability remained acceptable. These findings support the need for larger prospective studies to better define optimal treatment sequencing in focal-onset DRE."

Journal • CNS Disorders • Epilepsy

Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatment. (PubMed, Epilepsy Behav) - P2 | "Participants taking cenobamate who achieved ≥ 90%-< 100% responder rates were seizure-free for nearly 98% of days during the 5 years of the OLE. These results suggest that a high reduction of seizure burden can be achieved and maintained by many people with epilepsy taking cenobamate."

Clinical data • Journal • CNS Disorders • Epilepsy • Pain

Effectiveness of Cenobamate in Patients with Epileptic Encephalopathies: Analysis of a Single-center Cohort (AAN 2026) - "Cenobamate demonstrated meaningful seizure reduction in EEs and LGS, with favorable tolerability."

Clinical • CNS Disorders • Epilepsy

Efficacy and Safety of Adjunctive Cenobamate for the Treatment of Primary Generalized Tonic-clonic Seizures in Adults and Adolescents (AAN 2026) - P3 | "Adjunctive cenobamate 200 mg/day demonstrated efficacy and safety in treating PGTC seizures in patients ≥12 years old."

Clinical • CNS Disorders • Eosinophilia • Epilepsy

Delayed and Deferred Surgery Associated with Cenobamate Use in People with Drug Resistant Focal Epilepsy (AAN 2026) - "Patients with drug resistant focal epilepsy undergoing evaluation for epilepsy surgery may benefit from cenobamate. The delay-to-surgery identified among Hispanic and Latino patients suggests potential barriers to care warranting further investigation."

Surgery • CNS Disorders • Epilepsy • Infectious Disease • Novel Coronavirus Disease

Efficacy and Tolerability of Cenobamate in Treating Refractory Focal Epilepsy: Results From the 6-month Open-label Cenobamate in Focal Epilepsy Study (CIFES). (PubMed, Clin Neuropharmacol) - "These findings reinforce CNB as a valuable treatment option for patients with focal-onset drug-resistant epilepsy, supporting its integration into clinical practice. Further research is needed to evaluate long-term outcomes and its potential role as a first-line therapy."

Journal • CNS Disorders • Epilepsy

Beyond Clinical Trials: Cenobamate's Effectiveness in Diverse Epilepsy Populations (AAN 2026) - "Cenobamate significantly reduced seizure frequency in a real-world, clinically complex population with diverse backgrounds and comorbidities. These findings support its effectiveness beyond clinical trials and highlight the need for prospective studies to assess long-term outcomes and optimize treatment strategies for heterogeneous epilepsy populations."

Clinical • CNS Disorders • Depression • Developmental Disorders • Epilepsy • Mental Retardation • Vascular Neurology

Breaking the Cycle: GAD65 Autoimmune Epilepsy with Multidien Seizure Pattern in a Woman Misdiagnosed with Catamenial Seizures (AAN 2026) - "With the combination of rituximab, clobazam, and cenobamate, she achieved over 12 months free of bilateral tonic-clonic seizures, a significant decrease in focal seizures, and improved quality of life. Cyclical seizures in women with epilepsy should not always be presumed to be catamenial as this may incorrectly lead to harmful interventions. A multimodal approach to treatment of GAD65 TLE can result in improvement in seizures and quality of life."

Clinical • CNS Disorders • Epilepsy • Gynecology • Immunology

Polysubstance overdose with cenobamate, levetiracetam and clobazam: Insights into cenobamate toxicity. (PubMed, Seizure) - No abstract available

Journal • Anesthesia • CNS Disorders • Epilepsy

Knobloch Syndrome-1: An Uncommon Cause for Genetic Focal Epilepsy (AAN 2026) - "She was treated with lacosamide initially, with cenobamate later added for persistent seizures. Knobloch syndrome-1 is a rare clinically heterogenous disorder. COL18A1 is a collagen XVIII/endostatin gene highly expressed throughout the human eye. Pathogenic variations in this gene can also lead to abnormal neuronal migration."

CNS Disorders • Developmental Disorders • Epilepsy • Mental Retardation • Ophthalmology • COL18A1

Mortality Risk After Initiation of Cenobamate or Other Antiseizure Medications (AAN 2026) - "Objective: To retrospectively examine all-cause mortality in patients after initiating cenobamate vs mortality in patients treated with selected antiseizure medications (ASMs) that have similar patterns of use in medication-resistant epilepsy.Background: A previous post-hoc analysis of survival in a clinical trial cohort showed that the all-cause standardized mortality ratio (SMR) for cenobamate-treated patients was 1.32 (95% CI: 0.84-2.0), which was not significantly different from the general population.Design/ De-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated therapeutic doses of cenobamate or another selected ASM (brivaracetam, clobazam, lacosamide, eslicarbazepine, or perampanel) between 1/1/2020-12/5/2024. Patients treated with cenobamate at therapeutic doses had lower mortality rates than patients treated with selected comparable ASM."

CNS Disorders • Epilepsy

Phase 1, Open-label, Fixed-sequence, Bidirectional, Pharmacokinetic (PK) Drug-drug Interaction (DDI) Study Between Cannabidiol (CBD) and Cenobamate (CNB) in Healthy Adult Participants (AAN 2026) - "Objective: Evaluate PK DDIs between CBD and CNB.Background: Plant-derived highly purified CBD (Epidiolex®; 100 mg/mL oral solution) is approved for treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. No PK interactions were observed for CBD or CNB parent molecules. Clinical significance of reduced CBD metabolite exposures is unknown. These findings do not support CBD dose reduction when coadministered with CNB."

Clinical • P1 data • PK/PD data • CNS Disorders • Epilepsy

Epilepsy-related and All-cause Healthcare Resource Utilization After Initiation of Adjunctive Cenobamate (AAN 2026) - "Objective: To evaluate the comparative effect of initiating cenobamate vs selected antiseizure medications (ASMs, brivaracetam, clobazam, eslicarbazepine, lacosamide, or perampanel) on epilepsy-related and all-cause inpatient (IP) and emergency room (ER) utilization rates.Background: Cenobamate is an ASM approved for adults in the US that has demonstrated efficacy across focal seizure subtypes.Design/ A retrospective observational study using de-identified electronic health records from the Truveta database identified adults (≥18 years) with an epilepsy diagnosis who initiated cenobamate or another selected ASM between 1/1/202012/52024. Initiating cenobamate was associated with a significant reduction in both epilepsy-related and all-cause IP admissions and ER visits compared to propensity-matched patients who similarly could have initiated cenobamate but instead initiated other ASMs."

HEOR • CNS Disorders • Epilepsy

Refractory Autoimmune Encephalitis with Focal Status Epilepticus in a Patient with KLHL11 Antibody Syndrome (AAN 2026) - " The patient was found to have electroclinical seizures with focal status epilepticus despite extensive anti-seizure medication (ASM) therapy, including brivaracetam, lacosamide, valproic acid, phenobarbital, cenobamate, perampanel, and clobazam. This case illustrates the recurrent and refractory nature of KLHL11 antibody-associated autoimmune encephalitis, particularly when complicated by drug-resistant epilepsy. Early recognition of recurrence and escalation of immunotherapy, including rituximab, may be necessary in managing such cases. Comprehensive neurologic, immunologic, and oncologic evaluations are essential to guide ongoing therapy and improve clinical outcomes."

Clinical • CNS Disorders • Epilepsy • Germ Cell Tumors • Immunology

An Assessment of Acute Pharmacodynamic Drug-drug Interactions (PD-DDIs) Between Cannabidiol (CBD) and Cenobamate (CNB) in a Mouse Model of Generalized Tonic Seizures (AAN 2026) - "Objective: To evaluate PD-DDIs between plant-derived highly purified CBD (Epidiolex®, active pharmaceutical ingredient) and CNB in a mouse maximal electroshock seizure (MES) model.Background: Synergistic antiseizure PD-DDIs between CBD and antiseizure medications (ASMs) like clobazam have been observed in mouse seizure models. The study reveals evidence for pharmacodynamic synergism between CBD and CNB."

PK/PD data • Preclinical • CNS Disorders • Epilepsy

Maternal and Fetal Outcomes of Cenobamate Use in Pregnancy: A Case Series (AAN 2026) - "This case series suggests that women on cenobamate can have a healthy pregnancy and child, but further studies and clearer guidelines for dosing and monitoring are needed to establish a more comprehensive risk-benefit profile."

Clinical • CNS Disorders • Epilepsy • Gynecology

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: SK Life Science, Inc. | Recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Nov 2025

Trial completion • Trial completion date • CNS Disorders • Epilepsy • Pediatrics

Long-term Efficacy of Adjunctive Cenobamate: Open-label Extension of a Randomized Clinical Study in a Multinational Asian Population (AAN 2026) - "Reductions in seizure frequency increased or were maintained during the 32-week OLE maintenance phase. The safety profile was generally consistent with the double-blind phase."

Clinical • CNS Disorders • Epilepsy • Infectious Disease • Novel Coronavirus Disease

Hyponatremia Due to Vasopressin-Independent Antidiuresis Caused by Oxcarbazepine But Not Eslicarbazepine and Corrected with Tolvaptan (NKF-SCM 2026) - "METHODS/CASE SUMMARY 35-year-old woman with seizure disorder on cenobamate and eslicarbazepine acetate chronically presented to an outside facility with suicidal ideation. There, the medication regimen was switched to oxcarbazepine and quetiapine due to the facility's formulary restrictions...CONCLUSION Oxcarbazepine can cause AVP-independent SIAD responsive to tolvaptan. Individual risk for hyponatremia needs to be taken into account when replacing/interchanging antiepileptics."

Cardiovascular • CNS Disorders • Epilepsy • Heart Failure • Nephrology • Suicidal Ideation

A Phase 1 Single-dose Bioavailability Study of an Oral Cenobamate Suspension Formulation (AAN 2026) - P1 | "The relative bioavailability of a 200-mg dose of cenobamate is comparable whether administered as a tablet or an oral suspension. Both formulations may be taken with or without food."

P1 data

Touch-Screen Automatisms With Stereotyped Postictal Texting Behavior In A Case Of Drug And Surgical Refractory Epilepsy (AAN 2026) - "Status post right anterior temporal lobectomy, she is now having only nocturnal seizures originating from the left temporal lobe while also on Cenobamate, Lacosamide, and Clobazam; Engel Classification IID.Design/ N/A N/A This case highlights a unique post-ictal behavior of repetitively texting the same contacts for the patient's home address. This case highlights a unique post-ictal behavior of repetitively texting the same contacts for the patient's home address. This behavior appears to be a reliable marker of the patient's ongoing focal seizures and may serve as a useful biomarker to track her response to treatment. A literature review demonstrates that texting behavior has never been reported in relation to ictal or post-ictal processes."

Clinical • CNS Disorders • Epilepsy